KINIKSA A BE-,000273235 Logo
BMG5269C1010
A2JMVJ
KNSA

KINIKSA A BE-,000273235

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 84,34 € (-3,49%). La mediana è 89,33 € (+2,22%).

Acquista
  11
Mantieni
  0
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Kiniksa significantly increases ARCALYST sales and advances IL-1 pipeline

    Kiniksa reported Q2 net sales of about $243 million for ARCALYST, an increase of $29 million versus the prior quarter and the strongest growth since market launch. The company says it is profitable and is targeting a positive annual cash‑flow trajectory. KPL-387 has entered the Phase III study of the PASTEURAL program with the goal of once‑monthly dosing and a possible launch in 2028–2029; KPL-1161 is being developed as a potential quarterly option. Kiniksa sees additional market potential in recurrent pericarditis and highlights a growing prescriber base and solid payer support. » Altro su de.investing.com


  • Kiniksa Pharmaceuticals reaches record high at $64.85

    Kiniksa Pharmaceuticals’ stock rose to a record high of $64.85 and is up 130.88% year-to-date. The company has a market capitalization of $4.96 billion and reported revenue growth of 57% in the past year. For Q1 2026, Kiniksa reported earnings per share of $0.27 (expectation $0.21) and revenue of $214.3 million (expectation $207.1 million). InvestingPro rates the stock close to its fair value but notes an overbought RSI. » Altro su de.investing.com


  • Kiniksa raises guidance after strong Q1 – ARCALYST revenue grows 56%

    Kiniksa reported ARCALYST revenue of US$214.3 million in Q1 2026 (up 56% year‑on‑year) and EPS of $0.27, beating expectations. The company raised its full-year guidance for net product sales of ARCALYST to US$930–945 million (previously US$900–920 million). Net income, operating margin and cash increased substantially; management highlighted market expansion, direct‑to‑consumer marketing and ongoing clinical programs KPL‑387 and KPL‑1161. The stock rose sharply after the results and is approaching its 52‑week high. » Altro su de.investing.com


  • Kiniksa reports strong Q1 2026 thanks to ARCALYST and raises full-year guidance

    Kiniksa recorded significant revenue growth from ARCALYST in Q1 2026 to $214.3 million (+56% y/y) and raised its full-year guidance to $930–945 million. Net income and operating income increased markedly; earnings per share were $0.27, beating expectations. The company broadened its prescriber base and now addresses patients with a first relapse; commercial momentum and pipeline candidates KPL-387 and KPL-1161 are expected to support further growth. Liquidity and the balance sheet improved, while higher revenue-linked collaboration costs and rising R&D spending temper the margin profile. » Altro su de.investing.com


  • Kiniksa Pharmaceuticals reaches profitability after strong Arcalyst growth, stock falls premarket

    Kiniksa Pharmaceuticals reported Q4 2025 revenue of $202.1 million (+65% versus Q4 2024) and a net profit of $14.2 million after a net loss in the year‑ago quarter. For full-year 2025 the company posted revenue of $677.6 million (+62%) and a net income of $59 million. The strong performance was driven mainly by Arcalyst; Kiniksa has $414.1 million in cash and plans to expand the IL‑1 franchise and advance KPL‑387. Despite the results, the stock fell 6.44% premarket to $44.34. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, KINIKSA A BE-,000273235 ha registrato ricavi pari a 252,47 Mln € e un utile netto di 41,8 Mln €
(EUR) settembre 2026
YoY
Ricavi 252,47 Mln 63,82%
Utile lordo 134,53 Mln 62,32%
Utile netto 41,8 Mln 166,08%
EBITDA 52,57 Mln 124,01%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
6,86 Mld €
Numero di azioni
78,57 Mln
Massimo/minimo a 52 settimane
90,06 € - 33,57 €
Dividendi No
Beta
0,08
Rapporto P/E
67,36
Rapporto PEG
0,35
Rapporto P/B
10,61
Rapporto P/S
8,00

Profilo aziendale

Kiniksa Pharmaceuticals, Ltd., un'azienda biofarmaceutica, si concentra sulla scoperta, l'acquisizione, lo sviluppo e la commercializzazione di farmaci terapeutici per pazienti affetti da malattie debilitanti con significative esigenze mediche insoddisfatte in tutto il mondo. I suoi candidati farmaci includono ARCALYST, un inibitore di interleuchina-1alfa e interleuchina-1beta, per il trattamento della pericardite recidivante, una malattia cardiovascolare infiammatoria; Mavrilimumab, un inibitore a base di anticorpi monoclonali che ha completato le sperimentazioni cliniche di Fase II per il trattamento dell'arterite a cellule giganti; Vixarelimab, un anticorpo monoclonale, attualmente in sperimentazione clinica di Fase 2a per il trattamento del prurigo nodulare, una condizione infiammatoria cronica della pelle; e KPL-404, un inibitore a base di anticorpi monoclonali dell'interazione CD40-CD154, un segnale di co-stimolazione delle cellule T fondamentale per la maturazione delle cellule B, il cambio di classe delle immunoglobuline e la risposta immunitaria di tipo 1. Kiniksa Pharmaceuticals, Ltd. è stata costituita nel 2015 e ha sede a Hamilton, nelle Bermuda.

Nome
KINIKSA A BE-,000273235
CEO
Sanj K. Patel
Sede centrale London, gl
Bermuda
Sito web
Settore
Materiali
Industria
Prodotti chimici
Quotazione in borsa
25/05/2018
Dipendenti 366

Simboli di borsa

Borsa Simbolo
NASDAQ
KNSA
🍪

Parqet  usa i cookie. Scopri di più